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Abstract 
 
Aim 
Anticoagulation is underused in older patients with atrial fibrillation (AF). 
Scoring systems such as CHA2DS2-VASc and HAS-BLED are recommended to 
guide clinicians in anticoagulation decisions, but patients’ frailty may be an 
under-recognized factor. We investigated the association between the Clinical 
Frailty Scale (CFS) and community anticoagulation prescribing habits in patients 
aged over 75 years with AF admitted acutely to hospital. 
 
Methods 
Data was gathered retrospectively over 3 months on individuals admitted under 
a medical team to a tertiary teaching hospital in the United Kingdom. 
Demographics, AF history, CHA2DS2-VASc, HAS-BLED and CFS were collected. 
Bivariable analysis compared anticoagulated and non-anticoagulated groups. 
Each component of the CHA2DS2-VASc and HAS-BLED scores, as well as frailty, 
age and gender were entered in a multivariable analysis.  
 
Results 
419 patients with known AF were included. 215 were not anticoagulated 
(51.3%) on admission. Non-anticoagulated individuals were older (median age 
87 (interquartile range (IQR) 7) vs 83 years (IQR 6), p<0.001), more likely to be 
frail (81.4% vs 52.5%, p <0.001) and had lower CHA2DS2-VASc scores (median 4 
(IQR 2) vs 5 (IQR 2), p=0.01). In the multivariable analysis frailty had the 
strongest effect against anticoagulation prescription (OR:0.77 95%CI 0.70-0.85, 
p<0.001) compared to other significant risk factors like age (OR:0.98 95%CI 
0.97-0.98, p<0.001) and bleeding risk (OR:0.85 95%CI 0.74-0.97, p=0.02). 
 
Conclusions 
Frailty is associated with non-prescription of anticoagulation, independently of 
CHA2DS2-VASc and HAS-BLED. It may be an important unmeasured factor in 
anticoagulation decisions. The utility of explicit frailty measurements in 
anticoagulation decisions and patient outcomes needs researching. 
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Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia in older people 
and its prevalence increases with age.1,2 It is a risk factor for ischaemic stroke 
and is a powerful predictor of disability, dementia and death due to the 
increased severity of cardioembolic strokes compared to other stroke 
aetiologies.2 Cardioembolic strokes constitute a disproportionate burden of the 
total cost of stroke, with a 2-fold increase in median total healthcare costs 
compared to non-AF stroke.3 As the population becomes older, the number of 
individuals with AF is set to increase with cardioembolic stroke imposing a 
greater burden on patients, families and healthcare resources.1,4 
 
Anticoagulation is the only licensed medication to reduce the risk of stroke 5 but 
due to the perceived increased risk of complications6,7 lower rates of 
anticoagulation use is seen, especially in older patients, with up to half not being 
anticoagulated.8,9 
 
Frailty is defined as a state of vulnerability to adverse outcomes from stressors 7 
and it is recognised that frail individuals may be more susceptible to medication 
side effects, 10 including those from anticoagulation. Clinical trials rarely include 
frail patients, therefore, deciding who would benefit from anticoagulation can be 
challenging. Despite risk scores such as CHA2DS2-VASc11 [which assigns 1 point 
where there is a history of congestive cardiac failure, hypertension, diabetes 
mellitus, vascular disease, age ≥65 years and female gender, and 2 points if age 
≥75 years or there is a history of prior stroke/ transient ischaemic attack (TIA)] 
and HAS-BLED12 [which assigns 1 point to uncontrolled hypertension 
>160mmHg systolic, abnormal renal or liver function, labile international 
normalised ratio (INR), age >65, use of antiplatelet/anticoagulation which may 
increase risk of bleeding and alcohol use defined as >8 drinks/week] guiding 
clinicians when weighing up the risk of stroke against the risk of bleeding 13, 
guidelines do not provide specific advice on anticoagulation decisions for frail 
older people who are more susceptible to adverse outcomes.14,15  
 
 
Our study investigated the association between clinical frailty as measured by 
the 9-point Clinical Frailty Scale (CFS)16 (Figure 1) and community 
anticoagulation prescribing habits in patients aged 75 years and over, admitted 
acutely to hospital. An understanding of the relationship between clinical frailty 
and community prescribing of anticoagulants, independently of recognised 
decision aid tools such as CHA2DS2-VASc and HAS-BLED, may help elucidate the 
importance of the frailty syndrome in AF, as well as aiding the development of 
future clinical decision-making tools that are more appropriate for this 
vulnerable population. 
 
Method 
 
Data collection 
We conducted a retrospective observational study in a 1,000-bed teaching 
hospital in England, between 1st January and 31st March 2014. Inclusion criteria 
were age ≥75 years, admission under a general medical team, a history of AF, and 
a frailty score documented on admission. In our centre, the CFS is routinely 
collected in all non-elective admissions aged 75 years or more.17 
 
The CFS aims to capture the pre-admission, or baseline, frailty status and is 
calculated within 72-hours of admission by a clinician and recorded in the 
patient medical records. Patients were divided into two groups: ‘non-frail’ (CFS 
scores 1-4) and ‘frail’ (CFS scores 5-8). Data including patient age, sex, admission 
and discharge diagnosis, anticoagulation status, CHA2DS2-VASc, HAS-BLED and 
frailty scores were retrospectively collected from discharge letters.  
 
This study was part of a Service Evaluation Audit registered with our center’s 
Safety and Quality Support Department (project register number 3962). Formal 
confirmation was received that approval from the ethics committee was not 
required. 
  
 
 
Statistical analysis 
Data was analyzed using R (version 3.1.2). A p value <0.05 was considered 
statistically significant throughout data analysis. Initially bivariable comparisons 
for continuous data between anticoagulated and non-anticoagulated groups 
were tested for normality using Shapiro-Wilk testing, with subsequent analysis 
using the Student’s t-test or Mann-Whitney U-test for parametric and non-
parametric data respectively. Categorical data was analysed between cohorts 
using the chi-squared test. The multivariable logistic regression analysis 
included the following predictors of anticoagulation prescription: frailty, age, 
gender and the individual components of the CHA2DS2-VASc and HAS-BLED 
scores, rather than the cumulative scores, to avoid duplication. Due to the 
overlap in hypertension which has different definitions between the two scoring 
systems, we included hypertension as per the CHA2DS2-VASc score in the 
multivariable analysis. 
 
Results 
419 patients with known AF were included in the study. 215 were not 
anticoagulated (51.3%) on admission and 204 (48.7%) were anticoagulated. The 
use of warfarin (94.1%) heavily outnumbered both dalteparin (0.9%) and direct 
oral anticoagulants (DOACs) - dabigatran 4.1%; rivaroxaban 0.9%, apixaban 0%. 
In the frail cohort, 6 individuals were on DOACs compared to 5 in the non-frail 
group. The non-anticoagulated group were older (median age 87 years 
(interquartile range {IQR: Q3-Q1} 7) vs. 83 years (IQR 6), p<0.001) and had a 
higher prevalence of frailty (81.4% vs 52.5%, p <0.001). Individuals not admitted 
on anticoagulation had lower CHA2DS2-VASc scores (median 4 (IQR 2) vs. 5 (IQR 
2), p=0.01) compared to the anticoagulated group but there were no significant 
differences in HAS-BLED scores between the two groups (p=0.07) (Table 1). 
 
As clinical frailty increases, there are fewer anticoagulated individuals per CFS. 
(Figure 2) For example, at CFS 3 and 4, between 70-73% are on anticoagulation 
compared to CFS 7 and 8, where the proportion of anticoagulated individuals has 
dropped to 29% ad 7%, respectively. However, the same pattern is not seen with 
changes in the CHA2DS2-VASc or HAS-BLED scores. Our results show that having 
had a previous stroke or TIA meant that individuals were more likely to be on 
anticoagulation (p=0.01) and a history of prior bleeding or predisposition to 
bleeding meant that individuals were significantly less likely to be 
anticoagulated (p=0.001). The presence of other risk factors for stroke or 
bleeding as per the components of CHA2DS2-VASc and HAS-BLED scores did not 
differ between anticoagulated and non-anticoagulated groups (all p>0.05) (Table 
1). 
 
Multivariable analysis of frailty, age and gender along with the components of 
the CHA2DS2-VASc and HAS-BLED scores showed that individuals are more likely 
not to be on anticoagulation at admission, if they are older, frailer and are felt to 
be at risk of bleeding. However, having had a previous stroke or TIA, or having a 
history of congestive cardiac failure were associated with being prescribed 
anticoagulation. (Table 2)  
 
Frailty was the strongest independent predictor of not being on anticoagulation 
at admission compared to age and bleeding risk (OR:0.77 95%CI 0.70-0.85, 
p<0.001), emphasizing that frail individuals are 23% less likely to be 
anticoagulated on admission to hospital. 
 
Discussion 
Our study explored the association between clinical frailty and community 
anticoagulation prescription habits in patients aged over 75 years admitted 
acutely to hospital. Nearly half the patients aged over 75 years in our study were 
not on anticoagulation, with frailty, age and bleeding risk emerging as 
independent predictors of non-anticoagulation. Multivariable analysis suggested 
that frailty was the strongest predictor for not being on anticoagulation at 
admission even more so than bleeding risk. This indicates that despite explicit 
frailty measurements not being routinely conducted in the community, a clinical 
impression of an individual as being frail is negatively associated with 
anticoagulation prescription. 
 
Our results highlight the important role frailty plays anticoagulation decisions, 
and the low rates of anticoagulation observed in this study highlight that making 
such decisions in frail older individuals is challenging. Previous studies report 
that clinician reluctance to prescribe anticoagulation, because of the difficulty in 
choosing between stroke and bleeding risk, is a major reason for under-
treatment18–20, suggesting that more help and guidance is needed. However, 
specific geriatric characteristics that would allow safer prescription of 
anticoagulation have not been determined and existing guidelines are drawn 
from results of those with greater physiological reserve and as such are less 
likely to suffer adverse outcomes.10   
 
This highlights the need for safer and more reliable methods of assessing the 
risks and benefits of anticoagulation in frail individuals, including a greater 
understanding of the implications of frailty in such decisions. In large 
epidemiological studies, the frailty phenotype has been validated as a predictor 
of short and long-term adverse outcomes, including death21,22 and the CFS has 
been shown to have accuracy in predicting in-hospital adverse outcomes.17 
Because frail individuals develop numerous deficits across multiple domains of 
disease, relying on rigid scoring systems such as CHA2DS2-VASc and HAS-BLED, 
which contain overlapping risk factors for both stroke risk and bleeding risk, 
may be less applicable in frail cohorts.  
 
Our study has some limitations. Being a single-site study with a relatively small 
sample size of individuals admitted acutely to hospital, the individuals in the 
study may not be representative of the broader population. By nature of being a 
retrospective study, data collection may be limited by the record keeping, though 
the effects of this are limited by excluding patients without discharge summaries 
or recorded frailty scores, which includes those who died in hospital. 
 
Safer and more reliable methods of assessing the risks and benefits of 
anticoagulation in the frail older population would be useful in clinical practice. 
Frailty scores are not routinely measured in primary or secondary care, yet they 
may offer more flexibility and judgement to the clinician to make personalised, 
holistic decisions. In our study, increasing clinical frailty was associated with a 
lower proportion of individuals on anticoagulation, which suggests that 
clinicians already have an inherent idea of the concept of frailty and increased 
adverse outcomes. This is further supported by previous studies that show 
measured frailty scales correlate well with a clinician’s initial global assessment 
of frailty. 23 Because of the complexity of treatment in the older population, we 
propose that additional information gained from explicit frailty measurements 
may translate into clearer decision-making about anticoagulation. Further work 
is required to determine whether such assessments of frailty, and their role in 
determining anticoagulant prescribing, affects clinical outcomes. 
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Figure1 
Each patient admitted to hospital over >75 years have their clinical frailty 
calculated on admission as per the 9-point Clinical Frailty Scale. 
Available from: http://geriatricresearch.medicine.dal.ca/pdf/Clinical Faily 
Scale.pdf 
 
 
Figure 2 
The number and proportion of individuals not anticoagulated (black) compared 
to anticoagulated (white), when separated by clinical frailty scale, CHA2DS2-VASc 
and HAS-BLED scores.  
 
 
 
 
 
  
  
Table 1. Patient demographics data and bivariable analysis for significance 
between not-anticoagulated and anticoagulated groups. 
 
 
 
Not anticoagulated 
215 
Anticoagulated 
204 
Significance 
Frail 175 (81.4%) 107 (52.5%) p<0.001 
Median Age 87 (IQR 7) 83 (IQR 6) p<0.001 
Male 93 (43.3%) 96 (47.1%) p=0.43 
Median CHA2DS2-VASc 4 (IQR 2) 5 (IQR 2) p=0.01 
Congestive cardiac failure 58 (27.0%) 65 (31.9%) p=0.27 
Hypertension 146 (67.9%) 147 (72.1%) p=0.35 
Diabetes 45 (20.9%) 48 (23.5%) p=0.52 
Stroke/Transient ischemic 
attack 
56 (26.0%) 77 (37.7%) p=0.01 
Vascular disease 49 (22.8%) 55 (27.0%) p=0.32 
Median HAS-BLED 1 (IQR 1) 1 (IQR 1) p=0.07 
Liver abnormalities* 1 (0.005%) 2 (0.01%) p=0.53 
Renal abnormalities** 12 (0.06%) 14 (0.07%) p=0.59 
Prior bleeding or predisposition 37 (0.17%) 14 (0.07%) p=0.001 
Labile INR*** 2 (0.009%) 6 (0.03%) p=0.13 
Alcohol >8 drinks/week 1 (0.005%) 3 (0.01%) p=0.29 
Medication with bleeding 
risk**** 
5 (0.02%) 3 (0.01%) p=0.52 
 
As per the HAS-BLED scoring criteria: *cirrhosis or Bilirubin >2x Normal or 
AST/ALT/ALP >3x Normal, ** Dialysis dependent, previous transplant, 
creatinine >2.26 mg/dL or >200 µmol/L, *** Unstable/high International 
Normalized Ratio (INR), Time in Therapeutic Range < 60%, **** Antiplatelet 
agent/ NSAID use  
 
Table 2. Multivariable analysis of odds ratios for anticoagulation 
 
 Odds ratio for 
anticoagulation (95% CI) 
Significance 
Frail 0.77 (0.70-0.85) p<0.001 
Age 0.98 (0.97-0.98) p<0.001 
Male 0.98 (0.89-1.06) p=0.59 
CHA2DS2-VASc   
Congestive cardiac failure 1.12 (1.02-1.24) p=0.02 
Hypertension 1.05 (0.95-1.15) p=0.37 
Diabetes 0.94 (0.84-1.04) p=0.24 
Stroke/Transient ischemic 
attack 
1.19 (1.09-1.31) p<0.001 
Vascular disease 1.04 (0.94-1.14) p=0.51 
HAS-BLED   
Liver abnormalities* 0.91 (0.53-1.55) p=0.72 
Renal abnormalities** 1.06 (0.88-1.26) p=0.55 
Prior bleeding or predisposition 0.85 (0.74-0.97) p=0.02 
Labile INR*** 1.34 (0.98-1.84) p=0.07 
Alcohol 1.45 (0.92-2.30) p=0.11 
Medication with bleeding 
risk**** 
0.80 (0.58-1.10) p=0.17 
 
As per the HAS-BLED scoring criteria: *cirrhosis or Bilirubin >2x Normal or 
AST/ALT/ALP >3x Normal, ** Dialysis dependent, previous transplant, 
creatinine >2.26 mg/dL or >200 µmol/L, *** Unstable/high International 
Normalized Ratio (INR), Time in Therapeutic Range < 60%, **** Antiplatelet 
agent/ NSAID use 
